DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,871 filers reported holding DANAHER CORPORATION in Q3 2021. The put-call ratio across all filers is 1.50 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $683,994,648 | +12.5% | 2,756,931 | +8.8% | 1.04% | +16.2% |
| Q2 2023 | $608,174,916 | +3.3% | 2,534,062 | +8.5% | 0.90% | -5.2% |
| Q1 2023 | $588,674,454 | -15.0% | 2,335,639 | -10.4% | 0.94% | -21.9% |
| Q4 2022 | $692,169,973 | -3.9% | 2,607,829 | -6.5% | 1.21% | -11.8% |
| Q3 2022 | $720,617,000 | -1.5% | 2,789,956 | -3.3% | 1.37% | +4.5% |
| Q2 2022 | $731,382,000 | -12.2% | 2,884,909 | +1.6% | 1.31% | +4.0% |
| Q1 2022 | $833,077,000 | -9.6% | 2,840,067 | +1.4% | 1.26% | -4.2% |
| Q4 2021 | $921,124,000 | +1.6% | 2,799,683 | -6.0% | 1.32% | -6.5% |
| Q3 2021 | $906,916,000 | +11.3% | 2,978,966 | -1.9% | 1.41% | +11.0% |
| Q2 2021 | $814,598,000 | +25.0% | 3,035,469 | +4.9% | 1.27% | +16.7% |
| Q1 2021 | $651,471,000 | -5.1% | 2,894,400 | -6.3% | 1.09% | -10.9% |
| Q4 2020 | $686,492,000 | -7.8% | 3,090,354 | -10.6% | 1.22% | -16.7% |
| Q3 2020 | $744,565,000 | +8.7% | 3,457,784 | -10.8% | 1.46% | +0.5% |
| Q2 2020 | $685,117,000 | +21.5% | 3,874,441 | -4.9% | 1.46% | -1.4% |
| Q1 2020 | $563,751,000 | -15.2% | 4,073,051 | -6.0% | 1.48% | +7.7% |
| Q4 2019 | $665,021,000 | +8.9% | 4,332,949 | +2.5% | 1.37% | +0.9% |
| Q3 2019 | $610,695,000 | -18.6% | 4,228,307 | -19.4% | 1.36% | -18.7% |
| Q2 2019 | $750,124,000 | +8.3% | 5,248,563 | +0.0% | 1.67% | +3.6% |
| Q1 2019 | $692,640,000 | +4.3% | 5,246,479 | -18.5% | 1.61% | -8.0% |
| Q4 2018 | $663,878,000 | -5.7% | 6,437,917 | -0.6% | 1.75% | +15.5% |
| Q3 2018 | $703,739,000 | -44.2% | 6,476,522 | -49.3% | 1.52% | +5.6% |
| Q2 2018 | $1,260,144,000 | +103.2% | 12,770,006 | +101.6% | 1.44% | -0.3% |
| Q1 2018 | $620,104,000 | -39.9% | 6,333,407 | -43.0% | 1.44% | +25.5% |
| Q4 2017 | $1,031,180,000 | +122.5% | 11,109,462 | +105.6% | 1.15% | +7.5% |
| Q3 2017 | $463,429,000 | +5.0% | 5,402,531 | +3.3% | 1.07% | +3.7% |
| Q2 2017 | $441,192,000 | +30.9% | 5,228,018 | +32.7% | 1.03% | +30.5% |
| Q1 2017 | $336,917,000 | +16.3% | 3,939,172 | +5.8% | 0.79% | +13.2% |
| Q4 2016 | $289,715,000 | +16.2% | 3,721,935 | +17.0% | 0.70% | +16.5% |
| Q3 2016 | $249,391,000 | +19.0% | 3,181,406 | +53.3% | 0.60% | +17.6% |
| Q2 2016 | $209,555,000 | +48.6% | 2,074,796 | +39.6% | 0.51% | +52.2% |
| Q1 2016 | $141,001,000 | +0.8% | 1,486,408 | -1.3% | 0.34% | +6.0% |
| Q4 2015 | $139,853,000 | +3.8% | 1,505,742 | -4.8% | 0.32% | +5.0% |
| Q3 2015 | $134,734,000 | -14.7% | 1,581,196 | -14.3% | 0.30% | -5.0% |
| Q2 2015 | $157,936,000 | +779.7% | 1,845,264 | +772.6% | 0.32% | +780.6% |
| Q1 2015 | $17,953,000 | -10.4% | 211,464 | -9.6% | 0.04% | -12.2% |
| Q4 2014 | $20,046,000 | -48.2% | 233,879 | -54.1% | 0.04% | -50.0% |
| Q3 2014 | $38,699,000 | +4.8% | 509,329 | +8.6% | 0.08% | +3.8% |
| Q2 2014 | $36,917,000 | -0.9% | 468,905 | -5.6% | 0.08% | -6.0% |
| Q1 2014 | $37,246,000 | -4.9% | 496,613 | -2.1% | 0.08% | -10.6% |
| Q4 2013 | $39,160,000 | +49.8% | 507,245 | +34.5% | 0.09% | +34.3% |
| Q3 2013 | $26,135,000 | +11.9% | 377,028 | +2.1% | 0.07% | +2.9% |
| Q2 2013 | $23,364,000 | – | 369,108 | – | 0.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |